南新制药
(688189)
| 流通市值：24.09亿 | | | 总市值：24.09亿 |
| 流通股本：2.74亿 | | | 总股本：2.74亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 83,154,434.61 | 61,846,347.67 | 40,624,818.43 | 263,284,800.95 |
| 营业收入 | 83,154,434.61 | 61,846,347.67 | 40,624,818.43 | 263,284,800.95 |
| 二、营业总成本 | 138,946,104.66 | 93,637,777.93 | 47,665,234.41 | 328,725,287.15 |
| 营业成本 | 55,348,509.22 | 36,563,058.1 | 19,500,318.95 | 119,555,045.75 |
| 税金及附加 | 1,820,173.75 | 1,291,448.89 | 651,355.19 | 4,872,018.12 |
| 销售费用 | 24,541,835.55 | 18,023,006.09 | 7,116,773.68 | 107,735,297.69 |
| 管理费用 | 30,887,241.66 | 21,211,408.14 | 9,475,797.47 | 49,214,286.47 |
| 研发费用 | 27,300,905.81 | 17,554,291.71 | 10,420,828.81 | 48,807,332.82 |
| 财务费用 | -952,561.33 | -1,005,435 | 500,160.31 | -1,458,693.7 |
| 其中:利息费用 | 2,223,516.64 | 1,448,716.65 | 1,239,472.21 | 5,401,505.42 |
| 其中:利息收入 | 3,254,491.46 | 2,521,816.33 | 717,396.82 | 6,973,543.55 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -4,366,052.08 | -275,386.3 | - | - |
| 资产处置收益 | 2,228,555.38 | 1,799,150.21 | - | 594,628.23 |
| 资产减值损失(新) | -4,848,544.02 | -3,555,852.62 | -875,547.7 | -41,297,260.04 |
| 信用减值损失(新) | -14,482,340.33 | -10,528,947.5 | -444,442.19 | -283,696,828.82 |
| 其他收益 | 1,303,971.03 | 399,934.48 | - | 1,776,230.06 |
| 四、营业利润 | -75,956,080.07 | -43,952,531.99 | -8,360,405.87 | -388,063,716.77 |
| 加:营业外收入 | 9,378.1 | 313.45 | 303,555.8 | 83,264.89 |
| 减:营业外支出 | 171,598.96 | 16,395.96 | 10,151.54 | 656,606.92 |
| 五、利润总额 | -76,118,300.93 | -43,968,614.5 | -8,067,001.61 | -388,637,058.8 |
| 减:所得税费用 | -341,011.36 | -142,099.2 | 34,507.62 | 8,636,797.03 |
| 六、净利润 | -75,777,289.57 | -43,826,515.3 | -8,101,509.23 | -397,273,855.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -75,777,289.57 | -43,826,515.3 | -8,101,509.23 | -397,273,855.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -68,633,808.25 | -40,002,316.74 | -8,028,308.26 | -356,903,643.41 |
| 少数股东损益 | -7,143,481.32 | -3,824,198.56 | -73,200.97 | -40,370,212.42 |
| 扣除非经常损益后的净利润 | -66,491,537.94 | -41,731,433.79 | -8,288,432.62 | -358,530,972.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.25 | -0.15 | -0.03 | -1.3 |
| (二)稀释每股收益 | -0.25 | -0.15 | -0.03 | -1.3 |
| 九、综合收益总额 | -75,777,289.57 | -43,826,515.3 | -8,101,509.23 | -397,273,855.83 |
| 归属于母公司股东的综合收益总额 | -68,633,808.25 | -40,002,316.74 | -8,028,308.26 | -356,903,643.41 |
| 归属于少数股东的综合收益总额 | -7,143,481.32 | -3,824,198.56 | -73,200.97 | -40,370,212.42 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |